SARS-CoV-2 Infections, Clinical Characteristics, and Related Risk Factors: The First 8 Months Surveillance Study Conducted in Southwest Ethiopia

SARS-CoV-2感染、临床特征及相关危险因素:在埃塞俄比亚西南部开展的前8个月监测研究

阅读:1

Abstract

Coronavirus disease 2019 (COVID-19) is caused by a severe acute respiratory syndrome coronavirus (SARS-CoV-2) and became pandemic after emerging in Wuhan, China, in December 2019. We aimed to investigate the prevalence, clinical characteristics, and risk factors for SARS-CoV-2 infections in districts of southwest Ethiopia. A study was conducted on COVID-19 surveillance data in the diagnostic center of the southwest district of Ethiopia from July 1, 2020, to February 30, 2021. A total of 10 618 nasopharyngeal specimens were tested for SARS-COV-2 using the detection of unique sequences of virus RNA by reverse transcriptase PCR. Data were entered into Epidata version 3.1 and analyzed using SPSS version 25. Logistic regression was used to determine the relationship between COVID-19 and risk factors, with a significance level of P = 0.05. A total of 10 618 individuals were tested for SARS-CoV-2. Of these, 419 (3.9%) patients tested positive for SARS-CoV-2. Among a total of 419 patients who tested positive for SARS-CoV-2, 80.2% were asymptomatic, 264 (63.0%) were males, and 233 (55.6%) were aged 19 to 35 years. Comorbidity was present in 37 (8.8%). The risk of getting SARS-CoV-2 infections was increased with male sex (AOR = 1.248; 95% CI: 1.007, 1.547), health workers (AOR = 3.187; 95% CI: 1.960, 5.182), prisoners (AOR = 2.118; 95% CI: 1.104, 4.062), and comorbid conditions (AOR = 2.972; 95% CI: 1.649, 5.358), such as diabetes (AOR = 4.765; 95% CI: 1.977-11.485) and other respiratory problems (AOR = 3.267; 95% CI: 1.146-9.317). Despite the fact that overall laboratories confirmed prevalence of SARS-CoV-2 infections in the study area was low and dynamic, it was spread to all zones of the study area. This highlights the importance of implementing the most effective public health strategies to prevent the further spread and reduce the burden of SARS-CoV-2 infections.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。